Boston Scientific (BSX) Tops Q4 EPS by 4c, Beats on Revenue; Offers FY25 EPS Guidance
Tweet
Share
E-mail
Get Alerts BSX Hot Sheet
Price: $45.29 +0.76%
Revenue Growth %: +6.3%
Financial Fact:
Operating expenses: 1.16B
Today's EPS Names:
DTGI, CRMT, MAYS, More
Revenue Growth %: +6.3%
Financial Fact:
Operating expenses: 1.16B
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Boston Scientific (NYSE: BSX) reported Q4 EPS of $0.70, $0.04 better than the analyst estimate of $0.66. Revenue for the quarter came in at $4.56 billion versus the consensus estimate of $4.41 billion.
GUIDANCE:
Boston Scientific sees FY2025 EPS of $2.80-$2.87, versus the consensus of $2.81.
For earnings history and earnings-related data on Boston Scientific (BSX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kalshi in early talks for IPO - The Information
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Accenture (ACN) Tops Q3 EPS by 8c, Misses on Revenue; Offers FY26 EPS Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
